Stock LEXICON PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases Lexicon Pharmaceuticals, Inc. Nasdaq

Equities

US5288721047

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director
AQ
Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes
AQ
Data From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association
AQ
Analysis of INPEFA® (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology
AQ
Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association
AQ
Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024
AQ
New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction
AQ
Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024
AQ
Lexicon: Q1 Earnings Snapshot
AQ
Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
AQ
Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals
AQ
Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024
AQ
Lexicon Pharmaceuticals to Host 2024 Investor Day
AQ
Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
AQ
Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo
AQ
New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease
AQ
Lexicon: Q4 Earnings Snapshot
AQ
Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update
AQ
Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities
AQ
Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LXRX Stock
  4. Stock
  5. News Lexicon Pharmaceuticals, Inc.
  6. Press Releases